Testicular germ cell-induced autoimmune orchitis is characterized by inflammatory cell infiltration followed by disturbance of spermatogenesis. Experimental autoimmune orchitis (EAO) is an animal model for human immunological male infertility; delayed-type hypersensitivity (DTH) response plays a key role in its induction. Interleukin-10 (IL-10) is a regulatory cytokine that is critical in preventing organ-specific autoimmune inflammation. To determine the effects on EAO of human IL-10 (hIL-10) gene transfer, C3H/He mice immunized by unilateral testicular injury were administered intramuscular (i.m.) injections of adeno-associated viral (AAV) vector-encoding hIL-10 on the day of immunization. Serum hIL-10 was detected beginning at 1 week postinjection, and peaked at 3 weeks. Histological examinations showed a significantly low incidence of orchitis and disturbance of spermatogenesis in AAV hIL-10-treated mice, and the DTH response to autologous testicular cells was significantly suppressed. Immunohistochemical analysis of IFN-g and IL-2, T-cell-associated cytokines, in the spleen and testes revealed significantly fewer cytokine-expressing cells after treatment. We conclude that a single i.m. administration of AAV hIL-10 significantly suppresses EAO and hypospermatogenesis by regulating cell-mediated immunity in the testes.
Introduction
Among approximately one-third of infertile couples, the origin of infertility is believed to be primarily in the male partner. 1 A considerable number of cases are characterized by idiopathic male infertility, a disturbance of spermatogenesis that is without obvious causes at the time of diagnosis. Recently, testicular autoimmunity is considered to be a significant cause of idiopathic infertility, since cases of human autoimmune orchitis with lymphocytic infiltration and spermatogenic disturbance have been reported. [2] [3] [4] Murine experimental autoimmune orchitis (EAO) can be regarded as a model of human immunologic infertility induced by immunization with testicular germ cells (TGC) in normal mice. [5] [6] [7] Although the precise immunopathogenesis responsible for the autoimmune process are not fully understood, delayed-type hypersensitivity (DTH) responses against autologous TGC antigens play main roles in the onset or progress of EAO. [5] [6] [7] The induction of antigen-specific DTH response is caused by T-cell-mediated cellular immunity. Therefore, the central contribution of CD4Th1 cells and their cytokines to the development of DTH response 8, 9 suggests that these cells and their cytokines, such as IFN-g and IL-2, may be involved in the pathogenesis of testicular autoimmunity.
Interleukin-10 (IL-10) was originally discovered as a factor produced by mouse CD4Th2 cells, which was capable of inhibiting the production of proinflammatory cytokines, including IFN-g and IL-2, by CD4Th1 cells. The fact that IL-10 is an immunoregulatory cytokine 10 with potential therapeutic value for organ-specific autoimmune inflammatory disease [11] [12] [13] [14] strongly suggest that IL-10 has the potential to suppress autoimmune inflammation occurring in the testes.
Gene therapy has been used in clinical trials for human diseases and represents a novel and attractive alternative to conventional therapies. Our group and others have demonstrated the feasibility of using adenoviral and adeno-associated viral (AAV) vectors to deliver therapeutic genes to animals and humans. 15, 16 One of the advantages of using an AAV vectors is the ability to extend the period of transgene expression, compared with adenoviral vector-mediated gene expression. 17, 18 Another is recognized as having some superiority to other vectors with regard to their safety and efficiency, without known pathology (see Appendix A). 17, 18 Since humoral substances such as cytokine have been considered suitable for use in AAV-mediated gene therapy, 19, 20 we attempt prevention of EAO onset by the intramuscular (i.m.) human IL-10 (hIL-10) gene administration. Moreover, we investigated immunomoderatory effect of AAV-mediated hIL-10 gene therapy in EAO model.
Results

hIL-10 expression following in vivo administration of AAV viral vectors
In the present study, the hIL-10 gene was used to construct the recombinant AAV (rAAV) vector. Serum levels of hIL-10 in AAV hIL-10-treated mice rose significantly beginning on day 7 (P ¼ 0.005), peaked on day 21 (P ¼ 0.005), and then tended to decrease on day 42 (P ¼ 0.005) (Figure 1a ). Levels of mIL-10 were not affected during observation in all groups (Figure 1b) . Gene-transferred hIL-10 was specifically quantified using the ELISA method, which had no crossreactivity to endogenous mIL-10.
Suppression of EAO and hypospermatogenesis by AAV-mediated hIL-10 gene therapy
The effect of the treatment on EAO and hypospermatogenesis was examined by assessing histological appearances on days 21, 28, and 42. On testicular sections from phosphate-buffered saline (PBS)-or AAV LacZ-treated mice, interstitial infiltration of lymphocytes, desquamation of the germinal epithelium, and disturbance of spermatogenesis were first observed on day 28 ( Figure  2a ) and progressed on day 42 after treatment ( Figure 2b ). In contrast, most areas of AAV hIL-10-treated testes were free of orchitis and impairment of spermatogenesis on days 28 and 42 (Figure 2c ), but occasionally, foci of mild inflammatory cell migration were observed. On day 42, the testes obtained from PBS-or AAV LacZ-treated mice showed severe atrophy compared to those of AAV hIL-10-treated mice (Figure 2e ).
The mean score and incidence of EAO and hypospermatogenesis on day 42 are summarized in Table 1 . Both EAO and hypospermatogenesis score were significantly reduced (P ¼ 0.0003, P ¼ 0.0002) in AAV hIL-10-treated groups compared to the control groups. The results showed that disease incidence and progress were suppressed by AAV hIL-10 administration.
Effect of AAV hIL-10 treatment on DTH responses to TGC
DTH is an in vivo T-cell-dependent immune response manifested as an inflammatory reaction at the site of antigen deposition that reaches peak intensity 24-48 h after antigenic challenge; it represents an important source of information concerning in vivo T-cell function. Thus, in the present study, we evaluated DTH responses to TGC antigens to investigate cellular immune responses in vivo and compared the degrees of DTH in relation to the length of time after treatment. In the control groups (PBS or AAV LacZ), positive DTH reactions at the hind footpads were detected on day 7, peaked on day 21, and remained high on day 42 ( Figure  3 ). After AAV hIL-10 treatment, mild suppression of DTH responses was observed on day 7, and there was significant suppression from day 21 (P ¼ 0.009) to day 42 (P ¼ 0.008) compared to the control groups. These results indicated that cellular immune responses were significantly suppressed by the hIL-10, whereas there were not significant differences in DTH reactions between the PBS-and AAV LacZ-treated groups.
Prevention of proinflammatory cytokine expression in splenic and testicular lymphocyte after AAV hIL-10 treatment
In an attempt to detect T-cell-associated cytokines in the spleen and testes in vivo, immunohistochemical analysis was performed using anti-mouse IFN-g or IL-2 antibodies in AAV LacZ and AAV hIL-10 mice. In the white pulp of the spleen, cytokine-producing cells were present primarily in the periarteriolar lymphoid sheath around the central arteriole. In sections from AAV LacZ-treated mice, numerous IFN-g-or IL-2-positive cells were seen on day 42 after injection ( Figure 4a 
Discussion
EAO has been studied as an animal model of human immunological male infertility. [5] [6] [7] Recent studies reported that treatment using anti-inflammatory cytokines, 21 antibodies against proinflammatory cytokines, 22 and immunosuppressants 23 prevented the onset of EAO. In this study, we showed the utility of rAAV-mediated Interleukin-10 suppresses autoimmune orchitis M Watanabe et al hIL-10 gene delivery as a method of suppressing autoimmune orchitis and hypospermatogenesis. The hIL-10 gene was used to construct the rAAV vector, since we preliminarily confirmed that neither local immunoreactive changes in AAV hIL-10-injected muscle nor anti-hIL-10 antibody production in the serum on days 21 and 42 were detectable in the treated EAO model mice (data not shown). The activity of hIL-10 is comparable to endogenous mouse IL-10 and has been shown to be active in suppressing other experimental autoimmune disease.
13,24
The effects of IL-10 on autoimmune diseases using experimental models have been studied for years, but the results are somewhat confusing. In nonobese diabetic mice, IL-10 supplementation prevented autoimmune diabetes in some experimental protocols, 11, 12 whereas augmented it in others. 25 Similarly, the results of a recent study by Kaneko et al 26 of IL-10 in EAO differ from our present results. They showed that intraperitoneal administration of recombinant murine IL-10 augmented histological signs of EAO when administered for 6 consecutive days from days 15 to 20 after initial subcutaneous immunization with TGC. Although the exact reason for this discrepancy is unclear, differences in experimental protocol may affect the results. We used the rAAV hIL-10 system and injected the vectors i.m. on the immunization day. The serum hIL-10 level in AAV hIL-10 mice was significantly elevated beginning on postimmunization day 7 (P ¼ 0.005), and highly maintained after day 28 (P ¼ 0.005) when EAO process occurred and progressed in the control mice. Following suppression of DTH responses and cytokine production of IFN-g and IL-2 in the spleen and testes implied that both early and continuous elevation of the serum IL-10 might be important to modulate the immune response in the testes and reduce EAO onset.
Our results provide some clues toward understanding the mechanisms of cytokinetic actions in EAO prevention. Reductions in DTH responses by IL-10 treatment suggested that the mechanism for EAO prevention depends on the regulation of cell-mediated immunity involving alterations in testicular immunity. Aside from the effects in the testis, we recognized the potential of skeletal muscle production of IL-10 for influencing systemic cytokine regulation and immune responsiveness. Interestingly, the suppressive effects of IL-10 on production of specific proinflammatory cytokines such as mIFN-g and mIL-2 in splenic lymphocytes were consistent with the reduction of mIFN-g and mIL-2 serum levels. These systemic immunological changes probably contribute to the inhibition of lymphocyte migration and synthesis of IFN-g and IL-2 in testicular It is known that histological conditions of the germinal epithelium in the testis closely associated with fertility. Since the elevations of EAO/hypospermatogenetic scores can be associated with the onset of male infertility in EAO mice, 27 the improvement of inflammation demonstrated by the score reductions in AAV hIL-10-treated mice indicates the prevention of male infertility in the group. We also showed that the AAV dose (1 Â 10 10 particles/mouse) and the elevation and sustainment of serum IL-10 levels were therapeutic enough in the majority of our induced EAO models. Otherwise, the weight gain of AAV hIL-10-treated mice was similar to those of mice treated with PBS. No difference was found in liver histology between the two groups (data not shown). In addition, prolonged expression of IL-10 using AAV vector may elevate the risk of immunodeficiency following infection or tumor formation;
28,29 we could not observe such an elevation in preliminary experiments up to 6 months after treatment. Therefore, the observed therapeutic success without definite adverse effects supports the possibility of i.m. rAAV-mediated hIL-10 gene transfer approach.
Our study provides the first evidence that IL-10 is a potent immunoregulatory factor that effectively suppresses the development of EAO, and demonstrates the utility of cytokine gene therapy, afforded by rAAVmediated gene delivery, in altering the immune responses in the testes.
Materials and methods
Mice
C3H/HeN male mice, 9 to 12 weeks of age at study initiation, were purchased from SLC (Shizuoka, Japan). All animals were maintained under clean conditions with free access to food and water in the Laboratory Animal Center of Okayama University. They were allowed to adapt to their environment for 1 week before beginning the experiments.
rAAV type 2 vectors hIL-10 cDNA was amplified from the human cDNA library using primers that included forward (HindIII: 5 0 -CCCAAGCTTGGCATGCACAGCTCAGCACTG-3 0 ) and reverse (SalI: 5 0 -GCGTCGACTGGTTTCGTATCTTCAT TGTCA-3 0 ) restriction enzyme sequences. For the rAAV2 vector plasmid (CMV/hIL-10) construction, AAV vector plasmid (SF) derivatives of psub201 were employed. For rAAV2 LacZ virus production, Rn/LacZ (the Rous sarcoma virus long terminal repeat promotor) 30 vector plasmid was used. In an adenovirus-free system (Stratagene, La Jolla, CA, USA), rAAV2 virus vectors were propagated as described previously. 31 All virus preparations were purified by two successive bandings on CsCl gradients to ensure purity. Titer of respective AAV virus vectors was determined by DNA-PCR.
Preparation of TGC suspension
The viable TGC of syngeneic mice were used for DTH measurement as eliciting antigens. Testes were excised from mice after complete bleeding, teased with scissors, and squeezed by pipetting in cold Hanks' balanced salt solution (HBSS). Cell suspensions were passed though a 70 mm Cell Strainer (Becton Dickinson and Company, Franklin Lakes, NJ, USA) to remove residual large fragments. The TGC were harvested by centrifugation at 400 g for 10 min and washed three times in HBSS. The cells were resuspended in HBSS and adjusted to a designated concentration after measuring viability using Trypan blue dye exclusion.
Induction of EAO and treatments with rAAV
The mice were anesthetized with an intraperitoneal injection of 50 mg/kg of pentobarbital. For disease induction, the left testis was injured by 10 punctures with a 23-G needle to pierce through the tunica albuginea; the testis then was crushed fully with fingers. Immediately after immunization by the testicular injury, mice received particles (1 Â 10 10 ) of either AAV hIL-10 or AAV LacZ vector in a volume of 100 ml PBS by a single i.m. injection at the upper hind limbs. As controls, mice were injected with 100 ml PBS.
Measurement of DTH to TGC
Degrees of anti-TGC DTH were assessed by delayed footpad reaction on 0, 7, 14, 21, 28, and 42 days after treatments. Mice received an injection of 1 Â 10 6 autologous TGC in 50 ml of HBSS into the right hind footpad. The left hind footpad received HBSS only. After 24 h, the footpad thickness was measured with a dial thickness gauge (Ozaki Mfg, Tokyo, Japan). Reactions were expressed as the difference in thickness between the left and right footpads. Each group (normal, PBS, AAV LacZ, AAV hIL-10) consisted of five mice.
Histological and immunohistochemical procedures
On days 21, 28, and 42 after treatment, the mice were killed and right testes were removed, fixed with Bouin's solution, and embedded in paraffin without cutting the organs to avoid artificial damage to the testicular tissue. Sections (5 mm) were obtained at 100 mm intervals and stained with hematoxylin and eosin for histopathological assessment.
For immunohistochemical staining, tissue samples of the spleen and testes were obtained on day 42 and were snap-frozen. Frozen sections (5 mm) were cut at 100 mm intervals, dipped into cold acetone for 1 to 2 s, and stored frozen at À201C. The sections were fixed in cold acetone containing 0.2% H 2 O 2 for 10 min and were rehydrated in PBS with 1% bovine serum albumin. The biotinconjugated monoclonal antibodies used for immunostainings were anti-mouse IFN-g (XMG1.2, 4 mg/ml; PharMingen, San Diego, CA, USA) and anti-mouse IL-2 (JES6-5H4, 4 mg/ml; PharMingen), which were applied to tissue sections overnight at room temperature. The antibody-biotin conjugates were detected with an avidin-biotin-horseradish peroxidase complex (Nichirei, Tokyo, Japan) according to the manufacturer's instructions. The sections were incubated with diaminobenzidine (0.5 mg/ml) to detect enzyme activity.
Histological assessment
TGC-induced EAO after testicular injury is characterized by inflammatory cell infiltration followed by disturbance of spermatogenesis. All sections were examined on day 42 after treatment, stained with hematoxylin and eosin, and the severities of EAO and hypospermatogenesis Interleukin-10 suppresses autoimmune orchitis M Watanabe et al were divided into five grades as described previously. 7 The EAO was scored as follows: 0, no morphological change (no incidence); 1, scarce perivascular inflammatory cell infiltration; 2, several interstitial foci of inflammatory cells; 3, extensive inflammatory cell infiltration beneath the tunica albuginea that involves the interstitium and several seminiferous tubules; and 4, inflammation that replaces 50% or more of the whole area of testis section. Hypospermatogenesis was scored using the percentage of seminiferous tubules showing disappearance of mature germ cells, desquamation of germinal epithelium, and giant cell formation in the prepared section as follows: 0, 0% (no incidence); 1, 1-5%; 2, 6-25%; 3, 26-50%; and 4, 51-100%. In cases where the examined sections contained lesions of different EAO or hypospermatogenesis scores (eg lesions with EAO scores of 3 and 4), the most advanced lesion (in this case, 4) determined the scores of the mouse. Each injected group (PBS, AAV LacZ, AAV hIL-10) consisted of 10 to 12 mice. For quantification of mouse IFN-g and IL-2 expression, immunohistochemical sections of the spleen and testes were examined. Each group (normal, AAV LacZ, AAV hIL-10) consisted of five mice at an indicated time. The number of cytokine-secreting cells was correlated with the number of high-power fields ( Â 400) in which they were found, and the data were expressed as the number of positive cells/10 high-power fields.
Serum levels of hIL-10 and mouse cytokines
Blood samples obtained from hearts were allowed to clot, and the serum was immediately separated by centrifugation at 3000 g for 10 min and stored at À801C until assayed. The circulating levels of hIL-10 and mIL-10 were measured by ELISA kits (BioSource, Nivelles, Belgium and R&D Systems, Minneapolis, MN, USA) on 0, 7, 14, 21, 28, and 42 days after treatments. Values were expressed as IL-10 pg/ml by a standard curve using known amounts of recombinant hIL-10 or mIL-10. The limit of sensitivity of hIL-10 assay was 1 pg/ml. To calculate mean values, serum samples with hIL-10 below the limit of sensitivity were assigned minimum detectable concentration as a theoretical value. Serum levels of mouse IFN-g and IL-2 were measured by ELISA kits (BioSource International, Camarillo, CA, USA) on day 42. Each group (PBS or normal, AAV LacZ, AAV hIL-10) consisted of five mice.
Statistical analysis
Data are presented as the mean7s.e.m. Mann-Whitney U-test was used for statistical analysis of serum levels of IL-10, severity of EAO and hypospermatogenesis, DTH degrees, and quantification of mouse cytokine-expressing cells. Incidence of EAO and hypospermatogenesis were analyzed by Fisher's exact test. Differences were considered significant if Po0.05.
